We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mitochondrial Breakdown Promotes Death of Hypoxic Cells

By LabMedica International staff writers
Posted on 30 Nov 2011
Combining and breaking down of mitochondria are linked to how cells respond to changes in their environment. More...
A recent study has identified a molecular pathway critical to this process.

Investigators at the Sanford-Burnham Medical Research Institute (La Jolla, CA; USA) exposed cardiomyocyte cultures to low oxygen concentrations (hypoxia) that were similar to conditions found in the heart muscle following a heart attack.

They reported in the November 18, 2011, issue of the journal Molecular Cell that hypoxia-induced fission of mitochondrial membranes, dependent on availability of the mitochondrial scaffolding protein AKAP121.

Mitochondrial fission, which caused the heart cells to die, was stimulated when the ubiquitin ligase Siah2 reduced availability of AKAP121. Siah2 gene is a member of the seven in absentia homolog (Siah) family of proteins. The enzyme is an E3 ligase and is involved in ubiquitination and proteasome-mediated degradation of specific proteins. The activity of this ubiquitin ligase has been implicated in regulating cellular response to hypoxia.

Suppressing the activity of Siah2 in hypoxic cells or in mice increased AKAP121 levels, which reduced mitochondrial fission and resulted in death of fewer heart cells. Under hypoxic conditions, Siah2-deficient mice fared better than their normal counterparts did.

“Our work reveals key aspects to controlling mitochondrial dynamics in response to low oxygen tension,” said senior author Dr. Ze'ev A. Ronai, associate director the cancer center at the Sanford-Burnham Medical Research Institute. “By manipulating mitochondrial dynamics, we can help cells adapt to ischemic conditions in a way that might translate into new treatment options for patients who have experienced a heart attack.”

Research efforts are now focused on the pursuit of chemical compounds to inhibit Siah2 that can be further developed into new therapies to prevent or reverse cardiac damage.

Related Links:

Sanford-Burnham Medical Research Institute








New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
New
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Insights into sarcomatoid renal cell carcinoma point to broader use of common immunotherapies (Photo courtesy of Salgia NJ et al., Cancer Cell, 2025)

Novel Gene Signature Predicts Immunotherapy Response in Advanced Kidney Cancers

Sarcomatoid renal cell carcinoma (sRCC) is a rare, aggressive form of kidney cancer comprising about 5% of cases and is typically diagnosed at late stages. Resistant to most therapies, it has shown unusually... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.